JP2014167026A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014167026A5 JP2014167026A5 JP2014121055A JP2014121055A JP2014167026A5 JP 2014167026 A5 JP2014167026 A5 JP 2014167026A5 JP 2014121055 A JP2014121055 A JP 2014121055A JP 2014121055 A JP2014121055 A JP 2014121055A JP 2014167026 A5 JP2014167026 A5 JP 2014167026A5
- Authority
- JP
- Japan
- Prior art keywords
- sustained
- release preparation
- hydroxypropylmethylcellulose
- preparation according
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims 16
- 239000003405 delayed action preparation Substances 0.000 claims 12
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 12
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 11
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 11
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 11
- 238000009472 formulation Methods 0.000 claims 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims 6
- -1 2-hydroxyethoxy Chemical group 0.000 claims 5
- 239000003349 gelling agent Substances 0.000 claims 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims 3
- 239000001509 sodium citrate Substances 0.000 claims 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- 235000019359 magnesium stearate Nutrition 0.000 claims 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 2
- 239000003002 pH adjusting agent Substances 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 229940069328 povidone Drugs 0.000 claims 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 238000007906 compression Methods 0.000 claims 1
- 230000006835 compression Effects 0.000 claims 1
- UZVGSSNIUNSOFA-UHFFFAOYSA-N dibenzofuran-1-carboxylic acid Chemical compound O1C2=CC=CC=C2C2=C1C=CC=C2C(=O)O UZVGSSNIUNSOFA-UHFFFAOYSA-N 0.000 claims 1
- 239000011363 dried mixture Substances 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 229960001375 lactose Drugs 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 229940057948 magnesium stearate Drugs 0.000 claims 1
- 238000000465 moulding Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 229960001790 sodium citrate Drugs 0.000 claims 1
- 235000011083 sodium citrates Nutrition 0.000 claims 1
- NYERMPLPURRVGM-UHFFFAOYSA-N thiazepine Chemical compound S1C=CC=CC=N1 NYERMPLPURRVGM-UHFFFAOYSA-N 0.000 claims 1
- 238000005550 wet granulation Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9611328.7 | 1996-05-31 | ||
| GBGB9611328.7A GB9611328D0 (en) | 1996-05-31 | 1996-05-31 | Pharmaceutical compositions |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011243832A Division JP5888549B2 (ja) | 1996-05-31 | 2011-11-07 | 医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014167026A JP2014167026A (ja) | 2014-09-11 |
| JP2014167026A5 true JP2014167026A5 (enExample) | 2014-10-23 |
Family
ID=10794541
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP09541846A Pending JP2000511170A (ja) | 1996-05-31 | 1997-05-27 | 医薬組成物 |
| JP2006071695A Pending JP2006152006A (ja) | 1996-05-31 | 2006-03-15 | 医薬組成物 |
| JP2007030991A Pending JP2007119495A (ja) | 1996-05-31 | 2007-02-09 | 医薬組成物 |
| JP2011243832A Expired - Lifetime JP5888549B2 (ja) | 1996-05-31 | 2011-11-07 | 医薬組成物 |
| JP2014121055A Withdrawn JP2014167026A (ja) | 1996-05-31 | 2014-06-12 | 医薬組成物 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP09541846A Pending JP2000511170A (ja) | 1996-05-31 | 1997-05-27 | 医薬組成物 |
| JP2006071695A Pending JP2006152006A (ja) | 1996-05-31 | 2006-03-15 | 医薬組成物 |
| JP2007030991A Pending JP2007119495A (ja) | 1996-05-31 | 2007-02-09 | 医薬組成物 |
| JP2011243832A Expired - Lifetime JP5888549B2 (ja) | 1996-05-31 | 2011-11-07 | 医薬組成物 |
Country Status (31)
| Country | Link |
|---|---|
| EP (1) | EP0907364B1 (enExample) |
| JP (5) | JP2000511170A (enExample) |
| CN (3) | CN1142780C (enExample) |
| AR (1) | AR003662A1 (enExample) |
| AT (1) | ATE222105T1 (enExample) |
| AU (1) | AU727219B2 (enExample) |
| BR (1) | BR9709271A (enExample) |
| CA (1) | CA2251944C (enExample) |
| CZ (1) | CZ293760B6 (enExample) |
| DE (1) | DE69714739T2 (enExample) |
| DK (1) | DK0907364T3 (enExample) |
| EG (1) | EG24118A (enExample) |
| ES (1) | ES2182079T3 (enExample) |
| GB (2) | GB9611328D0 (enExample) |
| HR (1) | HRP970299B1 (enExample) |
| HU (1) | HU225152B1 (enExample) |
| ID (1) | ID18352A (enExample) |
| IL (1) | IL127222A (enExample) |
| MY (1) | MY120120A (enExample) |
| NO (1) | NO327801B1 (enExample) |
| NZ (1) | NZ332198A (enExample) |
| PL (1) | PL189887B1 (enExample) |
| PT (1) | PT907364E (enExample) |
| RU (1) | RU2201754C2 (enExample) |
| SI (1) | SI0907364T1 (enExample) |
| SK (1) | SK284131B6 (enExample) |
| TR (1) | TR199802483T2 (enExample) |
| TW (1) | TW550076B (enExample) |
| UA (1) | UA50772C2 (enExample) |
| WO (1) | WO1997045124A1 (enExample) |
| ZA (1) | ZA974735B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9922271D0 (en) | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Formulation |
| SE0003126D0 (sv) * | 2000-09-05 | 2000-09-05 | Astrazeneca Ab | Method of treatment |
| JP2004525109A (ja) | 2001-02-15 | 2004-08-19 | キング・ファーマシューティカルズ・インコーポレイティッド | 安定化された甲状腺ホルモン医薬組成物、及びその製法 |
| US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
| US7101569B2 (en) | 2001-08-14 | 2006-09-05 | Franz G Andrew | Methods of administering levothyroxine pharmaceutical compositions |
| SE0102855D0 (sv) * | 2001-08-27 | 2001-08-27 | Astrazeneca Ab | Method of treatment |
| EP1448169A1 (en) | 2001-11-07 | 2004-08-25 | Fujisawa Pharmaceutical Co., Ltd. | Method for improving dissolution of poorly dispersible medicaments |
| TW200735878A (en) * | 2005-11-18 | 2007-10-01 | Astrazeneca Ab | Pharmaceutical compositions |
| EP1976487A2 (en) | 2006-01-25 | 2008-10-08 | Astron Research Limited | Sustained release dosage form of phenothiazine derivatives containing channelizer |
| SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
| GB0618879D0 (en) * | 2006-09-26 | 2006-11-01 | Zysis Ltd | Pharmaceutical compositions |
| DE602007009036D1 (de) | 2007-02-14 | 2010-10-21 | Lesvi Laboratorios Sl | Pharmazeutische Zusammensetzungen mit Quetiapinfumarat |
| EP2131817A2 (en) | 2007-03-09 | 2009-12-16 | Synthon B.V. | Pharmaceutical composition of quetiapine fumarate |
| US20080287418A1 (en) * | 2007-05-16 | 2008-11-20 | Astrazeneca Ab | Extended Release Compositions and Methods for Their Manufacture |
| DK2262486T3 (da) | 2008-08-01 | 2013-03-25 | Krka Tovarna Zdravil D D Novo Mesto | Quetiapin sammensætning |
| EP2153834A3 (en) | 2008-08-07 | 2010-02-24 | Farmaprojects, S.A. | Extended release pharmaceutical compositions comprising quetiapine salts |
| DE102008046650A1 (de) | 2008-09-10 | 2010-03-11 | Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg | Quetiapin enthaltende Retardtablette |
| US20110280938A1 (en) * | 2009-01-05 | 2011-11-17 | Torrent Pharmaceuticals Limited | Sustained release pharmaceutical composition of quetiapine and process for preparation thereof |
| WO2010089259A2 (en) | 2009-02-04 | 2010-08-12 | Woerwag R&D Gmbh | Sustained release composition containing quetiapine |
| EP2233130A1 (en) * | 2009-03-23 | 2010-09-29 | Genepharm (Europe) Trading Limited | A sustained release oral composition of an antipsychotic agent |
| AR076907A1 (es) * | 2009-05-13 | 2011-07-20 | Wyeth Llc | Composiciones con liberacion rapida de farmaco |
| WO2011132008A2 (en) | 2010-04-22 | 2011-10-27 | EGIS Gyűgyszergyár Nyilvánosan Múködő Részvény társaság | Controlled release pharmaceutical composition |
| WO2011154118A1 (en) | 2010-06-07 | 2011-12-15 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Quetiapine prolonged-release tablets |
| DE102010033527A1 (de) | 2010-08-05 | 2012-02-09 | Acino Pharma Ag | Quetiapin-Tabletten |
| TR201008261A1 (tr) | 2010-10-08 | 2012-04-24 | Sanovel İlaç San. Ve Ti̇c. A.Ş. | Kontrollü salım gerçekleştiren ketiapin formülasyonları |
| CN102218042A (zh) * | 2011-05-26 | 2011-10-19 | 青岛黄海制药有限责任公司 | 富马酸喹硫平组合物的缓释片剂及其制备方法 |
| DE102011115690A1 (de) | 2011-10-11 | 2013-04-11 | Acino Pharma Ag | Quetiapin enthaltende Formulierungen |
| CN102406606B (zh) * | 2011-11-29 | 2013-01-23 | 海南美大制药有限公司 | 富马酸喹硫平脂质体固体制剂 |
| PL2822541T3 (pl) | 2012-09-10 | 2019-02-28 | Pharmathen S.A. | Kompozycja farmaceutyczna zawierająca nietypowy środek przeciwpsychotyczny i sposób jej wytwarzania |
| EP2848244A1 (en) | 2013-09-16 | 2015-03-18 | Yildiz Özsoy Erginer | Extended release tablet formulations of quetiapine |
| EP3310344A1 (en) * | 2015-06-19 | 2018-04-25 | Biotie Therapies, Inc. | Controlled-release tozadenant formulations |
| CN106187873B (zh) * | 2016-07-25 | 2019-11-05 | 宜春学院 | 一种芳胺基烷基氧类化合物及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607684D0 (en) * | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| US4775535A (en) * | 1986-04-04 | 1988-10-04 | Hans Lowey | Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics |
| US4756911A (en) * | 1986-04-16 | 1988-07-12 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
| EP0266707B1 (en) * | 1986-11-03 | 1992-01-22 | Schering Corporation | Sustained release labetalol tablet |
| IE59540B1 (en) * | 1987-01-09 | 1994-03-09 | Elan Corp | Sustained release capsule or tablet formulation |
| GB8705574D0 (en) * | 1987-03-10 | 1987-04-15 | Ici Plc | Preparation of thiazepine compound |
| US4983398A (en) * | 1987-12-21 | 1991-01-08 | Forest Laboratories, Inc. | Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates |
| IL92966A (en) * | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| SE9003902D0 (sv) * | 1990-12-07 | 1990-12-07 | Astra Ab | Solid dosage forms of a drug |
| IT1256651B (it) * | 1992-12-11 | 1995-12-12 | Giancarlo Santus | Composizione farmaceutica a rilascio controllato in sospensione liquida |
| JP3116970B2 (ja) * | 1991-06-12 | 2000-12-11 | 三菱東京製薬株式会社 | ペミロラストカリウムの徐放性製剤 |
| IT1256393B (it) * | 1992-11-17 | 1995-12-04 | Inverni Della Beffa Spa | Forme matriciali multistrato per il rilascio controllato di principi attivi |
| US5393765A (en) * | 1993-12-13 | 1995-02-28 | Hoffmann-La Roche Inc. | Pharmaceutical compositions with constant erosion volume for zero order controlled release |
| EP0759745A4 (en) * | 1994-05-13 | 1997-11-19 | Smithkline Beecham Corp | METHOD AND COMPOSITION FOR INCREASING FIXATION OF CALCIUM |
-
1996
- 1996-05-31 GB GBGB9611328.7A patent/GB9611328D0/en active Pending
-
1997
- 1997-05-15 GB GBGB9709761.2A patent/GB9709761D0/en active Pending
- 1997-05-27 CN CNB971949611A patent/CN1142780C/zh not_active Expired - Lifetime
- 1997-05-27 HU HU9902194A patent/HU225152B1/hu unknown
- 1997-05-27 TR TR1998/02483T patent/TR199802483T2/xx unknown
- 1997-05-27 JP JP09541846A patent/JP2000511170A/ja active Pending
- 1997-05-27 IL IL12722297A patent/IL127222A/xx not_active IP Right Cessation
- 1997-05-27 EP EP97924103A patent/EP0907364B1/en not_active Expired - Lifetime
- 1997-05-27 PL PL97330223A patent/PL189887B1/pl not_active IP Right Cessation
- 1997-05-27 DK DK97924103T patent/DK0907364T3/da active
- 1997-05-27 AU AU29675/97A patent/AU727219B2/en not_active Expired
- 1997-05-27 RU RU98123601/14A patent/RU2201754C2/ru active
- 1997-05-27 WO PCT/GB1997/001432 patent/WO1997045124A1/en not_active Ceased
- 1997-05-27 SI SI9730410T patent/SI0907364T1/xx unknown
- 1997-05-27 CA CA002251944A patent/CA2251944C/en not_active Expired - Lifetime
- 1997-05-27 UA UA98127026A patent/UA50772C2/uk unknown
- 1997-05-27 BR BR9709271A patent/BR9709271A/pt not_active Application Discontinuation
- 1997-05-27 ES ES97924103T patent/ES2182079T3/es not_active Expired - Lifetime
- 1997-05-27 AT AT97924103T patent/ATE222105T1/de active
- 1997-05-27 DE DE69714739T patent/DE69714739T2/de not_active Expired - Lifetime
- 1997-05-27 NZ NZ332198A patent/NZ332198A/xx not_active IP Right Cessation
- 1997-05-27 CZ CZ19983880A patent/CZ293760B6/cs not_active IP Right Cessation
- 1997-05-27 CN CNA2004100033798A patent/CN1511532A/zh active Pending
- 1997-05-27 CN CNA2006101016820A patent/CN101006985A/zh active Pending
- 1997-05-27 PT PT97924103T patent/PT907364E/pt unknown
- 1997-05-27 SK SK1639-98A patent/SK284131B6/sk not_active IP Right Cessation
- 1997-05-28 HR HR970299A patent/HRP970299B1/xx not_active IP Right Cessation
- 1997-05-28 MY MYPI97002306A patent/MY120120A/en unknown
- 1997-05-28 EG EG47397A patent/EG24118A/xx active
- 1997-05-29 ZA ZA9704735A patent/ZA974735B/xx unknown
- 1997-05-30 AR ARP970102352A patent/AR003662A1/es active IP Right Grant
- 1997-05-30 ID IDP971846A patent/ID18352A/id unknown
- 1997-06-04 TW TW086107689A patent/TW550076B/zh not_active IP Right Cessation
-
1998
- 1998-11-27 NO NO19985539A patent/NO327801B1/no not_active IP Right Cessation
-
2006
- 2006-03-15 JP JP2006071695A patent/JP2006152006A/ja active Pending
-
2007
- 2007-02-09 JP JP2007030991A patent/JP2007119495A/ja active Pending
-
2011
- 2011-11-07 JP JP2011243832A patent/JP5888549B2/ja not_active Expired - Lifetime
-
2014
- 2014-06-12 JP JP2014121055A patent/JP2014167026A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014167026A5 (enExample) | ||
| JP2009235073A5 (enExample) | ||
| CN103550165B (zh) | 一种含有利伐沙班的药物组合物及其制备方法 | |
| JP5787882B2 (ja) | 腸溶性錠剤 | |
| NZ607118A (en) | C-met modulator pharmaceutical compositions | |
| JP2016528302A5 (enExample) | ||
| WO2013054872A1 (ja) | ７－［４－（４－ベンゾ［ｂ］チオフェン－４－イル－ピペラジン－１－イル）ブトキシ］－１Ｈ－キノリン－２－オン又はその塩を含む錠剤 | |
| JP2015511635A5 (enExample) | ||
| RU2013125148A (ru) | Пероральная фармацевтическая таблетка с регулируемым высвобождением месалазина и способ ее получения | |
| JP5517327B2 (ja) | 口腔内崩壊錠用組成物 | |
| TWI739756B (zh) | 一種含有喹啉衍生物或其鹽的醫藥組成物 | |
| RU2016117186A (ru) | Комбинированная композиция, содержащая тадалафил и амлодипин | |
| JP6293315B2 (ja) | アリサルタン・イソプロキシル固体分散体及び該固体分散体を含有する医薬組成物 | |
| JP5790965B2 (ja) | カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤の製造方法 | |
| WO2011098194A3 (en) | Pharmaceutical mini-tablets for sustained release of flecainide acetate | |
| JP2017523149A5 (enExample) | ||
| WO2012017074A1 (en) | Oral pharmaceutical formulations of esomeprazole in the form of mups (multi unit pellets system) tablets | |
| JP2017520619A5 (enExample) | ||
| CN101854921B (zh) | 用于口服施用ppi的药物制剂 | |
| EP2139473A1 (en) | Valsartan tablet formulations | |
| JP6364478B2 (ja) | ドネペジル遊離塩基含有フィルム製剤及びその製造方法 | |
| JP2011012018A (ja) | 崩壊遅延が抑制されたパロキセチン塩酸塩水和物の経口投与用医薬組成物 | |
| RU2017119465A (ru) | Фармацевтические композиции, которые содержат лобеглитазон, для перорального введения | |
| JP2008531529A (ja) | テリスロマイシンを含む固形医薬組成物 | |
| CN104622821B (zh) | 解决溶出行为受制粒时间影响问题的莫西沙星片剂配方 |